In England, primary care services are now spending nearly £1 billion ($1.33 billion) on medicines for diabetes patient, as the net ingredient cost (NIC) for these drugs leapt £88 million to £956.7 million in 2015/16, according to data released today by NHS Digital.
Prescribing for Diabetes reports on and examines prescribing trends on medicines prescribed in primary care in England for the treatment and monitoring of diabetes during the period April 2005 to March 2016.
Key facts
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze